About: Modified ELISPOT: Modifications of the Elispot Assay for T Cell Monitoring in Cancer Vaccine Trials

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Modified ELISPOT: Modifications of the Elispot Assay for T Cell Monitoring in Cancer Vaccine Trials Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Modified ELISPOT: Modifications of the Elispot Assay for T Cell Monitoring in Cancer Vaccine Trials
Creator	Malyguine, Anatoli
Source	PMC
abstract	The use of the IFN-γ ELISPOT assay to evaluate cellular immune responses has gained increasing popularity, especially as a surrogate measure for CTL responses. We developed and validated some modifications of the IFN-γ ELISPOT assay to optimize immunological monitoring of various cancer vaccine trials. Taking into consideration that the main mechanism of cell-mediated cytotoxicity is the release of cytolytic granules that contain, among others, cytolytic protein Granzyme B (GrB), we developed the GrB ELISPOT assay. Extensive studies demonstrated that the GrB ELISPOT assay is specific, accurately measures the rapid release of GrB, is more sensitive than the 51Cr-release assay, and that it may be successfully applied to measuring CTL precursory frequency in PBMC from cancer patients. Assuming that immunological assays that demonstrate recognition of native tumor cells (tumor-specific) may be more clinically relevant than assays that demonstrate recognition of tumor protein or peptide (antigen-specific), we developed and validated the Autologous Tumor IFN-γ ELISPOT assay using PBMC from idiotype vaccinated lymphoma patients as effectors and autologous B cell lymphoma tumor cells as targets. The precursor frequency of tumor-reactive T cells was significantly higher in the postvaccine PBMC, compared with prevaccine samples in all patients tested. Furthermore, the specificity of these T cells was established by the lack of reactivity against autologous normal B cells. These results demonstrate the feasibility of evaluating tumor-specific T cell responses when autologous, primary tumor cells are available as targets. Modifications of ELISPOT assay described in this chapter allow more comprehensive assessment of low frequency tumor-specific CTL and their specific effector functions and can provide valuable insight with regards to immune responses in cancer vaccine trials.
has issue date	2005-01-01(xsd:dateTime)
bibo:doi	10.1007/1-4020-3623-x_8
has license	no-cc
sha1sum (hex)	92861b672bbd54127fc6aa57e3e3de1107fe17db
schema:url	https://doi.org/10.1007/1-4020-3623-x_8
resource representing a document's title	Modified ELISPOT: Modifications of the Elispot Assay for T Cell Monitoring in Cancer Vaccine Trials
has PubMed Central identifier	PMC7119983
schema:publication	Analyzing T Cell Responses
resource representing a document's body	covid:92861b672bbd54127fc6aa57e3e3de1107fe17db#body_text
is schema:about of	named entity 'specific' named entity 'protein' named entity 'developed' named entity 'granules' covid:arg/92861b672bbd54127fc6aa57e3e3de1107fe17db named entity 'compared' named entity 'popularity' named entity 'sensitive' named entity 'autologous' named entity 'Autologous' named entity 'tumor cells' named entity 'IFN-γ' named entity 'autologous' named entity 'higher' named entity 'cytolytic' named entity 'peptide' named entity 'immunological' named entity 'T cell' named entity 'IFN-γ' named entity 'studies' named entity 'validated' named entity 'GrB' named entity 'demonstrated' named entity 'accurately' named entity 'provide' named entity 'T Cell' named entity 'Modifications' named entity 'IFN-γ' named entity 'PBMC' named entity 'idiotype' named entity 'autologous' named entity 'cytolytic' named entity 'antigen' named entity 'GrB' named entity 'tumor' named entity 'surrogate measure' named entity 'CTL' named entity 'GrB' named entity 'tumor cells' named entity 'IFN-γ' named entity 'tumor cells' named entity 'Vaccination' named entity 'cytotoxic lymphocytes' named entity 'antibody' named entity 'effector' named entity 'tumors' named entity 'biotinylated' named entity 'gp100' named entity 'murine' named entity 'culture medium' named entity 'Pearson correlation coefficient' named entity 'CTL' named entity 'lytic' named entity 'CTL' named entity 'class II' named entity 'culture medium' named entity '37°C' named entity 'CTL' named entity 'secretion' named entity 'Tween 20' named entity 'Incubation time' named entity 'Cryopreserved' named entity 'Bethesda, MD' named entity 'gold standard' named entity 'IFN-γ' named entity 'cytolytic' named entity 'enzyme' named entity 'venous blood' named entity 'PVDF' named entity 'autologous' named entity 'cytotoxic T-lymphocyte' named entity 'LKB' named entity 'HEPES' named entity 'effector cell' named entity 'antigen' named entity 'Alkaline Phosphatase' named entity 'GrB' named entity 'vaccination' named entity 'protein' named entity 'tumor' named entity 'IL-2' named entity 'phenotype' named entity 'antigens'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software